A Fresh Frontier in Obesity Treatment: The Molecule That Promotes Weight Loss Without the Nausea

For millions of people, the promise of modern weight-loss medications comes with a significant catch: debilitating gastrointestinal side effects. While GLP-1 receptor agonists like semaglutide and tirzepatide have revolutionized obesity treatment, many patients struggle with nausea and vomiting, leading to high discontinuation rates. However, new research targeting a different pathway in the brain may offer a more tolerable alternative.

Scientists have identified a modified version of a small protein called octadecaneuropeptide (ODN) that promotes weight loss in rodents without the typical gastric distress associated with current blockbuster drugs. This breakthrough could potentially open doors for patients who cannot tolerate existing therapies.

What is Octadecaneuropeptide (ODN)?

Octadecaneuropeptide, or ODN, is a small protein naturally produced by cells in the hindbrain. Unlike GLP-1 therapies, which mimic hormones that affect both the brain and the digestive system, ODN targets a specific pathway tucked deep within the brain to regulate weight.

In a study published in Science Translational Medicine on July 23, 2025, researchers tested a modified version of this protein. The results were consistent across multiple small mammal species, including mice, rats, and shrews. Obese mice that received daily injections of the modified ODN for nine days showed consistent weight loss.

Solving the “Tolerability Gap” in Weight Loss Drugs

The primary appeal of ODN isn’t just that it works, but how it works. Current GLP-1 medications are highly effective but often cause nausea and vomiting. According to Caroline Geisler, Ph.D., a pharmacologist at the University of Kentucky and the study’s lead author, these side effects contribute to a discontinuation rate of over 50% among users.

The ODN compound did not trigger these nausea or vomiting behaviors in the test subjects. If these results translate to humans, ODN could serve as a critical alternative for the large population of patients who locate GLP-1 therapies intolerable.

Comparing ODN to Traditional GLP-1 Therapies

• Target Area: GLP-1s act on receptors in both the gut and brain; ODN targets a pathway deep in the hindbrain.
• Side Effect Profile: GLP-1s are frequently associated with nausea and vomiting; ODN showed no such gastric side effects in rodent models.
• Patient Retention: High dropout rates for GLP-1s (over 50%) craft the “easier to stomach” nature of ODN a significant clinical advantage.

The Path to Human Clinical Trials

While the results in rodents are promising, the protein currently requires frequent administration. Geisler and her colleagues at Syracuse University and the University of Pennsylvania are now working to tweak the ODN molecule to increase its longevity in the body. The goal is to initiate early human trials within the next two to three years.

The commercial potential is already being explored; biotech startup Coronation Bio has licensed the ODN derivatives to develop treatments for obesity and cardio-metabolic diseases.

Understanding the Biological Impact of Weight Loss

Beyond the specific molecule used, research into obese mice reveals how weight loss affects the body’s internal machinery. For instance, weight loss in obese mice has been shown to increase skeletal muscle mitochondrial energy efficiency, improving the way the body utilizes oxygen (OXPHOS efficiency) without drastically altering the mitochondrial proteome, according to research published in Life Metab.

However, the method of weight loss matters. A study involving C57BL/6J mice found that weight loss achieved through 30% caloric restriction led to cortical bone loss, trabecular thinning, and reduced bone formation. This suggests that while weight loss is generally beneficial for metabolic health, the strategy used to achieve it can impact skeletal integrity.

Key Takeaways

• New Molecule: Modified octadecaneuropeptide (ODN) promotes weight loss by targeting the hindbrain.
• No Nausea: Unlike GLP-1 drugs, ODN did not cause gastrointestinal side effects in mice, rats, or shrews.
• Human Potential: Human trials are targeted within two to three years as researchers work to make the protein last longer in the body.
• Metabolic Gains: Weight loss in obese models can improve mitochondrial energy efficiency in skeletal muscles.
• Skeletal Warning: Rapid weight loss via strict caloric restriction may be linked to bone mass reduction.

Frequently Asked Questions

Will ODN replace semaglutide or tirzepatide?

It is unlikely to replace them entirely but is intended to serve as an alternative for the approximately 50% of patients who cannot tolerate the gastrointestinal side effects of GLP-1 therapies.

When will this be available for humans?

The research is currently in the preclinical stage. Lead researchers aim to start early human trials within two to three years.

Does ODN cause muscle or bone loss?

The specific study on ODN focused on weight loss and the absence of nausea. However, separate research indicates that weight loss via caloric restriction can reduce bone formation and mass in obese mice.